<!-- Shared team overview - used by executive brief and suite briefs -->
<!-- Source of truth: Google Sheets CFI_CTAP_Data > Participants tab -->

## Research Team

CTAP brings together an interdisciplinary team spanning clinical trials operations, AI/machine learning, biomanufacturing, and disease-area expertise.

### Leadership

- **Lawrence Richer, MD, PhD** (PI) - Clinical Trials Director, Kipnes Health Research Institute

### Clinical Operations Leadership

| Facility | Director | Role in CTAP |
|----------|----------|--------------|
| Adult Clinical Investigation Unit | David Diachinsky | Phase I-IV trial execution, Suite 1 operations |
| Stollery Pediatric CIU | Christine Westerlund | Pediatric trials, rare disease unit |

### Core Facilities Leadership

| Facility | Director | Role in CTAP |
|----------|----------|--------------|
| Alberta Cryo-EM Facility | Dr. Howard Young / Dr. Kalyan Das | Structure-based insights |
| Glycomics Institute of Alberta | Dr. Lara Mahal | Glycan profiling for trials |
| TMIC Metabolomics | Dr. David Wishart / Dr. Liang Li | Metabolomic endpoints |
| Alberta Cell Therapy Manufacturing | TBD | GMP cell products |
| Canadian BioSample Repository | TBD | Biospecimen management |
| Drug Development & Innovation Centre | TBD | Formulation for trials |

### AI and Computational Biology

| Name | Role | Expertise | CTAP Contribution |
|------|------|-----------|-------------------|
| Dr. Lazar Atanackovic | Amii Fellow, ECE/Biochemistry | Generative modeling, causal inference, systems biology | Digital Twin Engine, In Silico Assessment Agent |
| Dr. Ross Mitchell | Amii Fellow, CIFAR AI Chair | Clinical AI, voice documentation, NLP | AI Scribe integration, clinical data capture |
| Amii CIFAR AI Chairs | Research partners | Reinforcement learning, health AI | CRAIDL agent development |
| Dr. Amber Simpson | Collaborator (Queen's â†’ UAlberta) | Radiomics, federated learning, computational biomarkers | Imaging/Radiomics Agent, multi-site AI |

### Drug Discovery & Computational Therapeutics

| Name | Role | Expertise | CTAP Contribution |
|------|------|-----------|-------------------|
| Dr. Khaled Barakat | Assoc. Professor, FPPS; CEO HEKA Therapeutics | Computational drug discovery, molecular dynamics, immune checkpoints | Structure-based drug design for trial targets; off-target toxicity prediction |
| Dr. Amir Tabatabaei Dakhili | Asst. Professor, FPPS | AI-driven drug design, energy metabolism, medicinal chemistry | SCOT inhibitor platform for diabetes trials; AI drug design methods |
| Dr. John Ussher | CRC, Pharmacotherapy of Energy Metabolism | Cardiovascular pharmacology, drug repurposing, Type 2 diabetes | Mechanistic endpoints for metabolic trials; drug repurposing approaches |
| Dr. Ratmir Derda | Professor, Chemistry; Founder, 48Hour Discovery | Phage display, high-throughput peptide screening | Discovery engine linking molecular hits to patient genomics |

### Key Partnerships

- **Amii (Alberta Machine Intelligence Institute)** - 10+ CIFAR AI Chairs for CRAIDL development; home to Dr. Atanackovic and Dr. Mitchell
- **Canadian VIGOUR Centre** - 50+ trials expertise for protocol design
- **Connect Care / Alberta Health Services** - Provincial EMR integration
- **AWS Calgary** - Secure cloud infrastructure

### EDI Commitment

CTAP's team includes Indigenous scholars, patient partners, and community representatives as co-investigators and governance members. We are committed to training 20% of HQP from Indigenous communities and underrepresented groups.
